A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|DRUG: Bevacizumab|DRUG: Entinostat|DRUG: Exemestane|DRUG: Fulvestrant|DRUG: Ipatasertib|DRUG: Tamoxifen|DRUG: Abemaciclib
Sponsor: Hoffmann-La Roche